Advertisement

Topics

M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer

2018-02-21 19:15:09 | BioPortfolio

Published on BioPortfolio: 2018-02-21T19:15:09-0500

Clinical Trials [631 Associated Clinical Trials listed on BioPortfolio]

M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas

Background: Pancreas cancer ranks 4th in all cancer-related deaths in the U.S. Gemcitabine is a standard treatment for it. M7824 blocks a pathway that prevents the immune system from effe...

Study of the Immune Response in Colon Adenocarcinoma

Duration of each part of the study per patient: - Screening: From 1 to 4 weeks - Sampling period (blood and tissue): 1 day - Follow-up by patient: 60 months - T...

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated. Phase I in this instance means MSB0011359C has never...

Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon

RATIONALE: Drugs used in chemotherapy, such as fluorouracil and leucovorin, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the gro...

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).

Background: - PD-1/PD-L1 signaling appears to be a major inhibitor of activated T cell anti-tumor immune responses. The rapid, deep and durable responses seen in various malignanc...

PubMed Articles [1698 Associated PubMed Articles listed on BioPortfolio]

miR-223-RhoB signaling pathway regulates the proliferation and apoptosis of colon adenocarcinoma.

MicroRNAs (miRNAs) can function as tumor suppressor or oncogenic genes. The putative targets of miR-223 include tumor suppressor gene, RhoB. Here we sought to investigate the role of miR-223-RhoB sign...

Changes in the Distribution of Cocaine- and Amphetamine-Regulated Transcript-Containing Neural Structures in the Human Colon Affected by the Neoplastic Process.

The present study analysed changes in the distribution pattern of cocaine- and amphetamine-regulated transcript (CART) in the enteric nervous system (ENS) of the human colon challenged by adenocarcino...

Case report: Retroperitoneal bronchogenic cyst as a diagnostic dilemma after colon cancer diagnosis.

A 52 year-old obese male presented with a moderately differentiated adenocarcinoma of the sigmoid colon. On staging CT, the patient was found to have a cystic lesion in the left retroperitoneum.

High association of Cryptosporidium spp. infection with colon adenocarcinoma in Lebanese patients.

The association between Cryptosporidium and human colon cancer has been reported in different populations. However, this association has not been well studied. In order to add new strong arguments for...

A rare case of oral metastasis of colon adenocarcinoma.

Metastatic carcinoma of the colon is frequently encountered. In the literature, metastasis of malignant tumors in the buccal cavity are rare. They represent less than 1% of oral malignant lesions.

Medical and Biotech [MESH] Definitions

The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON.

A lesion with cytological characteristics associated with invasive adenocarcinoma but the tumor cells are confined to the GLANDULAR EPITHELIAL CELLS of origin. Adenocarcinoma in situ of the CERVIX and the LUNG are the most common.

The segment of LARGE INTESTINE between ASCENDING COLON and DESCENDING COLON. It passes from the RIGHT COLIC FLEXURE across the ABDOMEN, then turns sharply at the left colonic flexure into the descending colon.

The segment of LARGE INTESTINE between TRANSVERSE COLON and the SIGMOID COLON.

A segment of the COLON between the RECTUM and the descending colon.

More From BioPortfolio on "M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial